Interim results of EDEMA2, a multicenter, open-label, repeat-dosing study of intravenous and subcutaneous administration of ecallantide (DX-88) in hereditary angioedema

被引：10

作者：

Lumry, W

Ritchie, B

Beck, T

Morrison, J

机构：

[1] Allergy & Asthma Specialists, Dallas, TX USA

[2] Univ Alberta, Edmonton, AB, Canada

[3] Dyax Corp, Cambridge, MA USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2006年 / 117卷 / 02期

关键词：

D O I：

10.1016/j.jaci.2005.12.715

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

699

引用

页码：S179 / S179

页数：1

共 50 条

[1] Results of a repeat-dosing study of intravenous and subcutaneous administration of ecallantide (DX-88), a recombinant plasma kallikrein inhibitor, in patients with hereditary angioedema.
Lumry, W.
Li, H.
Schneider, L.
Leflein, J.
Craig, T.
Morrison, J.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 98 (01) : A29 - A29
[2] Interim open-label results of EDEMA3sm:: A study of subcutaneous ecallantide in patients with Hereditary Angioedema
Li, H. H.
Levy, R. J.
McNeil, D. L.
Schmalbach, T. K.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : S276 - S276
[3] DX-88/19: FINAL RESULTS FROM THE OPEN-LABEL CONTINUATION STUDY OF ECALLANTIDE FOR ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA.
MacGinnitie, A. J.
Lumry, W.
Bernstein, J. A.
Li, H. H.
Riedl, M.
Soteres, D. E.
Craig, T. J.
Stolz, L.
Pullman, W. E.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A11 - A11
[4] ECALLANTIDE ADMINISTRATION AS 2 VS 3 INJECTIONS FOR HEREDITARY ANGIOEDEMA: RESULTS FROM THE DX-88/19 STUDY
Soteres, D. F.
Li, H. H.
Lumry, W.
Riedl, M.
Bernstein, J.
Craig, T. J.
MacGinnitie, A. J.
Pullman, W. E.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A111 - A112
[5] Ongoing open-label extension study of ecallantide for the treatment of acute attacks of hereditary angioedema: interim results
MacGinnitie, A.
Pullman, W.
Patrick, H.
ALLERGY, 2010, 65 : 13 - 14
[6] Results of a 2-stage, phase 3 pivotal trial, EDEMA3®:: A study of subcutaneous DX-88 (ecallantide), a plasma kallikrein inhibitor, in patients with hereditary angioedema (HAE)
Levy, R.
McNeil, D.
Li, H.
Hsu, F. I.
Horn, P.
Roberts, J.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S103 - S103
[7] Interim Results from Continuation-the Ongoing, Open-Label, Extension Study of Ecallantide for the Treatment of Acute Attacks of Hereditary Angioedema
MacGinnitie, A. J.
Pullman, W. E.
Horn, P. T.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2010, 125 (02) : AB165 - AB165
[8] EFFICACY OF ECALLANTIDE FOR THE TREATMENT OF ACUTE ATTACKS BY PRIMARY ATTACK LOCATION IN DX-88/19 (CONTINUATION)-THE OPEN-LABEL, EXTENSION STUDY
Craig, T. J.
Riedl, M.
Li, H. H.
Bernstein, J. A.
Lumry, W.
MacGinnitie, A. J.
Soteres, D. F.
Pullman, W. E.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A112 - A112
[9] Rebound or relapse rates in hereditary angioedema attacks treated with ecallantide in an open-label, repeat-treatment study
Soteres, D.
MacGinnitie, A.
Craig, T.
Bernstein, J.
Lumry, W.
Li, H.
Riedl, M.
Iarrobino, R.
Chyung, Y.
Shea, E.
Pullman, W.
ALLERGY, 2012, 67 : 138 - 138
[10] Subcutaneous DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema: results from the pivotal phase 3, double-blind, placebo-controlled EDEMA4 trial
Levy, R.
Lumry, W.
McNeil, D.
Li, H.
Horn, P.
Pullman, W.
ALLERGY, 2009, 64 : 120 - 121

← 1 2 3 4 5 →